Blockbuster Pathology Deal Sees Japan’s Miraca Holdings Pay $725 Million to Acquire C

[Anonymous]

There are several notable aspects to this acquisition. First, it brings a major Japanese player in clinical laboratory testing into the United States for the first time. That could mean tougher competition for such national medical laboratory companies as Quest Diagnostics Incorporated (NYSE: DGX), Laboratory Corporation of America (NYSE: LH), and Sonic Healthcare, Ltd., (ASX: SHL).

Second, because Miraca is paying a strong price for Caris, this deal will probably be used to support high valuations for anatomic pathology companies in the current marketplace. It is reported that annual revenue at Caris is $207 million per year and operating profit is $34 million. Thus, the purchase price of $725 million is 3.6 times Caris’ annual revenue and represents a multiple of 21.3 times operating profit. Private pathology group practices should take note of these significant facts.


Source: http://www.darkdaily.com/blockbuste...5-million-to-acquire-caris-diagnostics-102011

 

[Anonymous]

Re: Blockbuster Pathology Deal Sees Japan’s Miraca Holdings Pay $725 Million to Acqui

There are several notable aspects to this acquisition. First, it brings a major Japanese player in clinical laboratory testing into the United States for the first time. That could mean tougher competition for such national medical laboratory companies as Quest Diagnostics Incorporated (NYSE: DGX), Laboratory Corporation of America (NYSE: LH), and Sonic Healthcare, Ltd., (ASX: SHL).

Second, because Miraca is paying a strong price for Caris, this deal will probably be used to support high valuations for anatomic pathology companies in the current marketplace. It is reported that annual revenue at Caris is $207 million per year and operating profit is $34 million. Thus, the purchase price of $725 million is 3.6 times Caris’ annual revenue and represents a multiple of 21.3 times operating profit. Private pathology group practices should take note of these significant facts.


Source: http://www.darkdaily.com/blockbuste...5-million-to-acquire-caris-diagnostics-102011

Hopefully all these dolts starting these Gray Area private Pathologists labs will go out of business.

 

[Anonymous]

Re: Blockbuster Pathology Deal Sees Japan’s Miraca Holdings Pay $725 Million to Acqui

There are several notable aspects to this acquisition. First, it brings a major Japanese player in clinical laboratory testing into the United States for the first time. That could mean tougher competition for such national medical laboratory companies as Quest Diagnostics Incorporated (NYSE: DGX), Laboratory Corporation of America (NYSE: LH), and Sonic Healthcare, Ltd., (ASX: SHL).

Second, because Miraca is paying a strong price for Caris, this deal will probably be used to support high valuations for anatomic pathology companies in the current marketplace. It is reported that annual revenue at Caris is $207 million per year and operating profit is $34 million. Thus, the purchase price of $725 million is 3.6 times Caris’ annual revenue and represents a multiple of 21.3 times operating profit. Private pathology group practices should take note of these significant facts.


Source: http://www.darkdaily.com/blockbuste...5-million-to-acquire-caris-diagnostics-102011

WELL HERE IT GOES!! Just got a call from a recruiter that the HemePaths at Yale in Ct. are starting a "Flow Lab", they are looking to hire Sales reps from OHIO-Maine. Only plan on offering Flow related services to Oncology Offices....

How many of these are going to start up now??